Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 9, 2012
Event Date: January 8, 2012
Context: The company announced key 2012 goals for its RNAi therapeutics pipeline and provided updated cash guidance for the fiscal year ending December 31, 2011.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report references updated cash guidance for the year ended December 31, 2011, but the specific figures are contained in the attached press release (Exhibit 99.1) and are not detailed in the body of this Form 8-K.
Material Changes
No specific numerical material changes versus prior periods are disclosed in the text of this filing. The primary material event is the strategic announcement of 2012 pipeline goals and the revision of cash guidance.
Guidance, Outlook, and Risks
- Outlook: Management outlined key goals for the RNAi therapeutics pipeline for the year 2012.
- Guidance: Updated cash guidance was issued for the fiscal year ending December 31, 2011.
- Legal Disclaimer: The information in this Form 8-K and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated January 8, 2012) for the specific numerical values of the updated cash guidance.
- Verify the details of the 2012 RNAi therapeutics pipeline goals outlined in the press release.
- Confirm the company's current cash position relative to the updated guidance to assess liquidity runway.